Pre-earnings options volume in Arcturus Therapeutics (ARCT) is normal with calls leading puts 9:1. Implied volatility suggests the market is anticipating a move near 11.1%, or 97c, after results are released. Median move over the past eight quarters is 3.5%.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Is ARCT a Buy, Before Earnings?
- Arcturus Therapeutics Advances Cystic Fibrosis Study with ARCT-032
- Arcturus Therapeutics Advances with ARCT-810 Study for OTC Deficiency
- Cathie Wood Trims Exposure to AMD and Other U.S. Tech Favorites, Doubles Down on Baidu and Biotech Plays
- Coinbase, eBay upgraded: Wall Street’s top analyst calls